Abstract:There was very little high-level evidence about which radiation therapy (RT) regimen was more effective for prostate cancer after radical prostatectomy (RP). In 2011, we began the randomized, controlled, phase 3 trial to investigate the effect of dose intensified post-operative RT. Patients were randomly assigned to either 66Gy/33f or 72Gy/36f. The aim of current analysis was to compare toxicity, urinary continence recovery and biochemical outcomes. This trial recruited patients who had received RP for a histologically confirmed adenocarcinoma of the prostate, and who had stage pT3-4, positive surgical margins, pN+ or who had rising PSA of 0.2ng/ml following RP. Eligible patients were randomly assigned (1:1) to receive either 66Gy or 72Gy. IG-VMAT techniques was used. The primary endpoint was biochemical progression-free survival (PSA increase of 0.2 ng/ml or greater from the post-RT nadir, a continued rise in PSA despite RT or the initiation of salvage ADT). The second endpoints were acute and late toxicity, and urinary continence recovery. Genitourinary (GU) and gastrointestinal (GI) toxicity was assessed using RTOG-EORTC criteria. Incontinence was assessed by International Consultation on Incontinence Modular Questionnaire Short Form (ICIQ-SF) at start/end of RT and 1 year afterward. Between September 2011 and November 2016, 144 patients were randomly assigned, 71 to 66Gy group and 73 to 72Gy group. The median follow-up time was 42 months (range: 10-71 mos). 3-year biochemical progression-free survival was 73.8% vs. 76.6% in 66Gy vs. 72Gy group. For acute toxicity, no significant differences were seen between the two groups. Acute GU toxicity grade 1 and 2 were reported as 74.6% and 83.6%, 5.6% and 4.4% respectively. Late GU toxicity grade 1 and 2 were 18.3% and 8.2%, 8.5% and 11.0%. Grade 3 GU toxicity was observed in one patient in 72Gy group. For acute GI toxicity, these figures were 78.9% and 84.9%, 11.3% and 8.2%. Late GI grade 1 and 2 were 9.9% and 8.2%, 1.4% and 2.7%. No significant differences between both groups were seen for late GI and GU toxicity. At baseline 48 (33.3%) of patients were incontinent (16.7% mild, 13.9% moderate, 2.8% severe). Of these 48 patients, continence was recovery one year after RT by 33.3% vs. 28.6% with 66Gy vs. 72Gy. 63.0% vs. 66.7% of patients remained stable. Only 2 patients felt more seriously after RT. Our study suggested that dose-intensified RT was associated with low rates of acute and late grade 2-3 GU/GI toxicity, and had no obviously impact on one-year urinary continence recovery. However, the long-term survival outcomes needed to be further explored.

Genitourinary toxicity in patients receiving TURP prior to hypofractionated radiotherapy for clinically localized prostate cancer: A scoping review

Early Channel Transurethral Resection of the Prostate for Patients with Urinary Retention after Brachytherapy

Acute toxicity patterns and their management after moderate and ultra- hypofractionated radiotherapy for prostate cancer: A prospective cohort study

Effect of Prior Transurethral Prostate Resection (TURP) or Laser Enucleation (ThuLEP) on Radiotherapy-Induced Toxicity and Quality of Life in Prostate Cancer Patients Undergoing Definitive Radiotherapy

Rectum and Bladder Toxicity in Postoperative Prostate Bed Irradiation: Dose–Volume Parameters Analysis

Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer

Radiation-induced complex anterior urinary fistulation for prostate cancer: a retrospective multicenter study from the Trauma and Urologic Reconstruction Network of Surgeons (TURNS)

Toxicity And Biochemical Outcomes After Dose Intensified Post-Operative Radiation Therapy For Prostate Cancer: A Randomized, Controlled, Phase 3 Trial

Risk factors for the long‐term persistent genitourinary toxicity after stereotactic body radiation therapy for localized prostate cancer: A single‐center, retrospective study of 306 patients

Late genitourinary toxicity in salvage radiotherapy for prostate cancer after radical prostatectomy: impact of daily fraction doses

Phase I study of moderately hypo-fractionated intensity modulated radiotherapy after prostatectomy

The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B Study

[Short- and medium-term tolerance of hypofractionated prostate radiotherapy with simultaneous integrated boost]

Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection

Phase Ⅰ study of moderately hypo-fractionated intensity modulated radiotherapy after prostatectomy

Toxicity and Biochemical Outcomes of Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Results of a Randomized Phase III Trial

State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature

Toxicity of hypofractionated intensity-modulated radiotherapy in patients with prostate cancer

A preliminary toxicity study of different dose fractionation regimens in postoperative radiotherapy for prostate cancer

[Moderately hypofractionated dose escalation radiotherapy for localized prostate cancer, ESHYPRO: Results of a retrospective single-centre series evaluating safety and efficacy]

Urinary diversions after radiation for prostate cancer: indications and treatment